Merger will create Nasdaq-listed, clinical-stage therapeutic platform company developing new precision medicines for patient populations selected through Notable’s proprietary Predictive Precision Medicines Platform (“PPMP”)
Notable’s validated PPMP combines multi-dimensional biological assays and machine learning to bio-simulate a patient’s cancer treatment and predict their clinical response to the actual treatment
Notable has applied its PPMP to selecting and developing two clinical-stage therapeutic candidates in acute myeloid leukemia (“AML”); Phase 2a results for lead asset Volasertib in adult AML in platform-predicted responding patients expected in 3Q 2024
Leading healthtech-focused investors have committed an additional $10.3 million in a private placement, led by Builders VC, B Capital Group, Y Combinator, First Round Capital, and Founders Fund; Aggregate net transaction proceeds expected to fund planned operations into 2025
https://finance.yahoo.com/news/vbl-therapeutics-notable-labs-announce-120000861.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.